# EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Study · id `cardio:ct-nct06531824` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06531824](<https://clinicaltrials.gov/study/NCT06531824>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06531824

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 8371 participants.

## Technical summary

Registry record NCT06531824. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-30 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 8371 participants (enrolled count; ClinicalTrials.gov record NCT06531824, source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)
- Started: 2024-08-30 (actual) (ClinicalTrials.gov record NCT06531824, source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06531824, source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06531824, source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; China; Denmark; Germany; India; Italy; Japan; Malaysia; Mexico; New Zealand; Portugal; South Korea; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06531824, source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06531824-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- Condition: Kidney Disease, Chronic
- Intervention (Drug): BI 690517
- Intervention (Drug): Placebo matching BI 690517
- Intervention (Drug): Empagliflozin
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: 38e30be3b4829b7af63c9e6ff9324f2bcc9d674533252c3fd0dadbfc5c202e41
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
